Citrobacter amalonaticus: Genomics, Pathogenicity, and Antibiotic Resistance

Citrobacter amalonaticus is a gram-negative bacterium in the family Enterobacteriaceae that has shifted from clinical obscurity to genuine concern over the past decade, largely because of its growing arsenal of antibiotic resistance genes. While it accounts for a small fraction of hospital-acquired infections compared to better-known relatives like C. freundii or C. koseri, the strains turning up in clinical labs today carry resistance to carbapenems, colistin, and other last-resort drugs, sometimes all at once. Its genomics tell a story of a versatile organism that thrives in hospital plumbing, wastewater, and the human gut, picking up mobile resistance elements along the way.

Where It Fits in the Citrobacter Family

Citrobacter amalonaticus sits within a genus of about a dozen recognized species, several of which were only formally separated through DNA hybridization studies in the late 1990s. The species gets its name from its inability to ferment malonate, a biochemical quirk that historically set it apart on laboratory plates. Yet that same historical reliance on a handful of sugar-fermentation tests creates real identification headaches. A study evaluating conventional biochemical methods across 136 Citrobacter strains found that about 10% were misidentified as the wrong species within the genus, though the vast majority were correctly placed at the species level.¹ That error rate might sound modest, but in clinical microbiology it matters: treatment decisions hinge on getting the species right, and C. amalonaticus carries a different intrinsic resistance profile than, say, C. freundii.

Modern identification has improved considerably with MALDI-TOF mass spectrometry, a technique that identifies bacteria by their protein fingerprint in minutes rather than days. A comparison of biochemical versus MALDI-TOF methods on 153 Citrobacter strains showed MALDI-TOF correctly identified 95% unambiguously, outperforming conventional tests in both accuracy and speed.² The remaining discrepancies were almost always between closely related species within the C. freundii complex, not wild misassignments to other genera. For genomic-level certainty, whole-genome sequencing has become the gold standard. One recent clinical isolate initially defied easy classification: reference-database matching pointed toward a generic Citrobacter species, but phylogenomic analysis using a broader genome taxonomy database conclusively placed it as C. amalonaticus.³ The takeaway is that older identification pipelines can miss or mislabel this organism, which means historical infection data likely undercount it.

What Infections Does It Cause

The single largest case series on C. amalonaticus infections comes from a hospital surveillance study in Marseille, France, which tracked 36 patients over several years. Urinary tract infections dominated, accounting for roughly 80% of all episodes. Most infections were hospital-acquired, and the patient demographics were skewed: males outnumbered females, and nearly a third of all infected patients were young children.⁴ That pediatric overrepresentation is striking and suggests that immature immune defenses or neonatal hospitalization create a window of vulnerability.

The organism is not limited to urinary infections, though. Broader studies of Citrobacter bloodstream infections paint a sobering picture for patients whose defenses are compromised. A population-based study of over 550 episodes of Citrobacter bloodstream infection found a median patient age of 77 years and a 90-day mortality of 18%.⁵ While that study pooled multiple Citrobacter species, C. amalonaticus shares the same risk landscape of elderly, hospitalized, or catheterized patients. Septic shock, though occurring in only a small percentage of bloodstream episodes, is the single most powerful predictor of death. A separate cohort study of bloodstream infections caused by bacteria with AmpC-type resistance enzymes found that developing septic shock within 72 hours increased the odds of dying by roughly 70-fold.⁶

At the other end of the severity spectrum, C. amalonaticus can cause straightforward bladder infections in outpatients who have never been catheterized. A case report documented cystitis in an 87-year-old woman whose only predisposing factor was incomplete bladder emptying related to an overactive bladder. She responded to a standard course of levofloxacin.⁷ The authors emphasized how rare such community-acquired reports are, suggesting that clinicians may not think of C. amalonaticus when they see a positive urine culture from an outpatient, and the organism could be dismissed as contamination.

How It Sticks Around and Causes Harm

Like many opportunistic gram-negative bacteria, C. amalonaticus does not rely on a single dramatic toxin to cause disease. Instead, it uses a combination of adherence, biofilm formation, and immune evasion. Biofilm, the slimy matrix that bacteria build on surfaces like catheters and plumbing, is central to its persistence. Studies on closely related Citrobacter species have shown that biofilm formation is strongly temperature-dependent, with bacteria forming biofilms at the liquid-air interface and behaving quite differently at 37°C versus 25°C.⁸ That temperature sensitivity matters clinically: an organism colonizing the relatively cool environment of hospital water pipes behaves differently once it enters the warm human body.

The ability to adhere to human intestinal cells is another piece of the puzzle. Researchers studying multidrug-resistant Enterobacterales from organ transplant recipients found that Citrobacter strains could attach to colon cells in laboratory models, a prerequisite for gut colonization that can later seed bloodstream infections.⁸ For transplant patients on immunosuppressive drugs, that colonization-to-infection pipeline is a real clinical concern.

The Antibiotic Resistance Problem

This is where C. amalonaticus earns its place in infectious-disease conversations. The species naturally produces a chromosomal beta-lactamase enzyme that breaks down certain penicillins and early cephalosporins. That alone is manageable. What is not manageable is the organism’s increasingly documented ability to acquire plasmid-borne carbapenemase genes, which confer resistance to carbapenems, the antibiotics often reserved for the most serious gram-negative infections.

One of the most alarming clinical isolates reported was a C. amalonaticus strain from China carrying both bla_NDM-1, a gene encoding a metallo-beta-lactamase that destroys carbapenems, and mcr-1.5, a gene that confers resistance to colistin. Colistin is sometimes the last available drug for carbapenem-resistant infections, so co-resistance to both makes treatment options vanishingly thin. That isolate was resistant to imipenem, meropenem, multiple cephalosporins, aminoglycosides, and colistin simultaneously, while remaining susceptible to only a handful of agents including aztreonam and tigecycline.⁹ A clinician facing that antibiogram has very little room to maneuver.

More recently, C. amalonaticus isolates carrying bla_NDM-4, a variant of the NDM carbapenemase, were characterized in China. Genome analysis revealed that the NDM-4 gene sat on a novel plasmid type, indicating that the resistance machinery is still diversifying and may spread to other bacterial species.¹⁰ Separately, an isolate carrying bla_IMP-4, yet another carbapenemase, along with qnrS1, a gene associated with fluoroquinolone resistance, has been fully sequenced, showing that C. amalonaticus strains cluster with related strains in evolutionary analyses, which suggests clonal spread rather than purely random gene acquisition.¹¹

Perhaps the most dramatic case came from a single isolate that co-produced three different carbapenemases at once. Genomic analysis confirmed its identity as C. amalonaticus using phylogenomic methods after initial database comparisons were ambiguous.³ Triple carbapenemase producers are rare in any species, and their emergence in a relatively uncommon organism like C. amalonaticus underscores how mobile genetic elements can accumulate resistance genes across species barriers.

A Diagnostic Trap Worth Knowing About

One underappreciated consequence of C. amalonaticus biology involves rapid diagnostic testing for extended-spectrum beta-lactamases. The NG-Test CTX-M MULTI is a widely used immunochromatographic assay designed to detect CTX-M-type enzymes, the most common extended-spectrum beta-lactamases worldwide. However, C. amalonaticus (along with the related species C. farmeri) produces a chromosomally encoded beta-lactamase that cross-reacts with the test, generating false-positive results.¹²

In practice, this means that when the test flags a C. amalonaticus isolate as CTX-M positive, the lab cannot be sure whether the organism truly carries an acquired CTX-M gene or whether its natural enzyme simply triggered the assay. A false positive for CTX-M could lead a clinician to avoid cephalosporins that would actually work, or trigger unnecessary infection-control interventions. Labs working with Citrobacter species need to be aware of this pitfall and confirm positive CTX-M results with molecular methods when the species is C. amalonaticus or C. farmeri.

Life Outside the Hospital

C. amalonaticus is not exclusively a human pathogen. It occupies a range of environmental niches that matter both for understanding where resistance genes come from and for recognizing the organism’s biotechnological potential.

Wastewater appears to be a significant reservoir. One isolate from a sewage treatment facility demonstrated the ability to reduce perchlorate, an environmental contaminant from rocket propellant and certain fertilizers, through a dissimilatory pathway. The strain’s 16S ribosomal DNA sequence matched C. amalonaticus at 99.8% similarity.¹³ This means the organism can use perchlorate as a terminal electron acceptor for respiration, effectively detoxifying it, a capability that has attracted interest for bioremediation of contaminated groundwater and industrial waste.

Another environmental isolate, recovered from pharmaceutical wastewater, was shown to degrade paclitaxel, a widely used chemotherapy drug that persists in hospital effluent. This C. amalonaticus strain, named Rashtia, could use paclitaxel as its sole carbon source.¹⁴ Pharmaceutical compounds that linger in waterways pose ecological risks, and organisms capable of breaking them down have practical value in waste treatment, assuming safety can be managed given the species’ pathogenic potential.

On the agricultural side, a phytase enzyme originally cloned from C. amalonaticus has been engineered for use as a potential animal feed supplement. Phytases break down phytic acid in plant-based feeds, releasing phosphorus that livestock would otherwise not absorb. The C. amalonaticus phytase was expressed on the surface of yeast cells, where it showed high activity and unusual stability at acidic pH, properties that make it attractive for surviving passage through the stomach.¹⁵ This is a case where a gene from a pathogenic organism finds a benign second life in industrial biotechnology.

A Surprising Role in Gut Ecology

One of the more fascinating recent findings involves C. amalonaticus acting not as a pathogen but as a protective commensal. In a mouse model studying colonization by Citrobacter rodentium, an organism that mimics human intestinal pathogens, researchers found that about 35% of mice spontaneously cleared the pathogen from their gut after antibiotic treatment was stopped. These resistant mice harbored a bloom of commensal C. amalonaticus, which inhibited C. rodentium growth in a contact-dependent manner, both in the test tube and in the living gut.¹⁶

Contact-dependent killing is a theme in microbial competition: the attacking bacterium needs to physically touch its target to deliver toxic effectors. The finding reframes C. amalonaticus as a species that can, under certain conditions, function as a natural barrier against closely related pathogens in the intestinal lumen. It also raises the broader question of how antibiotic treatment, by wiping out commensal competitors like C. amalonaticus, inadvertently opens the door for harmful organisms. This dual identity, sometimes pathogen, sometimes protector, is a common paradox in the Enterobacteriaceae and complicates any simple narrative about whether a given species is “good” or “bad.”

Phage Therapy as an Emerging Option

With drug resistance narrowing antibiotic options, researchers have turned to bacteriophages, viruses that specifically infect and kill bacteria, as a potential therapeutic approach. Lab work combining phages with sublethal doses of antibiotics against C. amalonaticus showed synergistic killing: the combination was more effective than either phages or antibiotics alone, and the effect depended on antibiotic concentration. Even very low numbers of phages were sufficient to enhance killing when paired with the right antibiotic dose.¹⁷

This phage-antibiotic synergy approach is still in early stages for most bacterial pathogens, and C. amalonaticus is no exception. No human clinical trials have been reported for phage therapy targeting this species. But the lab results are encouraging for a reason beyond the obvious: phages are typically very host-specific, meaning a phage that kills C. amalonaticus will leave the rest of the patient’s gut flora undisturbed. That precision contrasts sharply with broad-spectrum antibiotics, which carpet-bomb the microbiome and, ironically, can promote the very resistance genes the treatment is trying to combat.

What Makes It Hard to Track Epidemiologically

Several features of C. amalonaticus make it slip through the surveillance nets built for more prominent pathogens. First, as covered above, older biochemical identification methods frequently confuse it with other Citrobacter species. Many clinical labs, particularly in resource-limited settings, still rely on automated panels that use biochemical reactions rather than MALDI-TOF or sequencing. Second, the organism does not currently have a dedicated multilocus sequence typing (MLST) scheme of its own; clinical isolates are sometimes typed using the C. freundii MLST scheme, a workaround that functions but limits the ability to track outbreaks within C. amalonaticus specifically.¹⁸ Third, because it is genuinely uncommon relative to E. coli or Klebsiella, individual hospitals may see only a few isolates per year, not enough to trigger a pattern-recognition alarm even when resistant strains are circulating.

The result is a surveillance blind spot. The resistance genes that C. amalonaticus carries, particularly NDM-type carbapenemases and MCR-type colistin resistance genes, are extensively tracked in E. coli and Klebsiella pneumoniae. When those same genes show up in a rare Citrobacter species, the finding may be published as a case report rather than triggering the kind of public health response it warrants. That matters because plasmids carrying these resistance genes do not respect species boundaries. A carbapenemase plasmid in C. amalonaticus today could be in E. coli tomorrow.

How Wastewater Connects Clinical and Environmental Strains

The environmental versatility of C. amalonaticus, its ability to degrade pharmaceuticals, reduce perchlorate, and persist in sewage, raises a practical question about the pipeline between hospital drains and community water. Hospital wastewater is known to be enriched in antibiotic-resistant bacteria and in the antibiotics themselves, creating selective pressure for resistance. An organism like C. amalonaticus, equally at home in a patient’s urinary tract and a wastewater treatment plant, is a plausible vehicle for shuttling resistance genes between clinical and environmental settings. The finding that environmental strains can degrade pharmaceutical compounds like paclitaxel¹⁴ confirms that strains persist in hospital effluent, exactly the environment where they encounter sub-inhibitory antibiotic concentrations that drive resistance evolution.

This ecological dimension is often missing from clinical discussions of antibiotic resistance, which tend to focus on patient-to-patient transmission within hospitals. For C. amalonaticus, the environmental reservoir may be at least as important as the clinical one. Surveillance efforts that sample only clinical isolates risk missing the broader reservoir of resistance circulating in water systems, agricultural runoff, and sewage treatment facilities where this organism naturally thrives.